<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7362761\results\search\testTrace\results.xml">
  <result pre="from their surface. An outbreak of a novel coronavirus 2019" exact="infection" post="has posed significant threat to the health and economies"/>
  <result pre="world. This article reviewed the viral replication, pathogenicity, prevention and" exact="treatment" post="strategies. With a lack of approved treatment options for"/>
  <result pre="pathogenicity, prevention and treatment strategies. With a lack of approved" exact="treatment" post="options for this virus, alternative approaches to control the"/>
  <result pre="Syndromeâ€&quot;Human coronavirus MERS-CoV (3â€&quot;5). The pandemic SARS-CoV-2 outbreak has caused" exact="infection" post="in over 8,000,000 individuals and over 400,000 deaths in"/>
  <result pre="virus was identified in record time, and the mechanisms of" exact="infection" post="were largely deciphered. These are the first steps to"/>
  <result pre="These are the first steps to develop the most important" exact="infection" post="control measures, in addition to prevention and hygiene (9)."/>
  <result pre="of the virus. SARS-COV-2 may be manifested as an asymptomatic" exact="infection" post="or mild to severe pneumonia (20). COVID-19 patients may"/>
  <result pre="disorders caused by SARS-COV-2 infection. The incubation period of SARS-COV-2" exact="infection" post="is ~5.2 days. There are general similarities in the"/>
  <result pre="or Northern blot hybridization targeting specific SARS-CoV-2 genes (25). Direct" exact="immunofluorescence" post="assay (IFA) is used to detect viral antigens present"/>
  <result pre="in SARS-CoV-2 infections (23). Some diagnostic features along with the" exact="treatment" post="targets are depicted in Figure 3. Figure 3 Some"/>
  <result pre="Targets and Treatments Using Drugs: Where we Stand Now COVID-19" exact="treatment" post="should primarily aim for the rapid disappearance of symptoms,"/>
  <result pre="of severe forms at risk of death (29). An effective" exact="treatment" post="for SAR-CoV-2 can follow one of the following strategies"/>
  <result pre="against SARS-CoV-2, as well as some positive results in the" exact="treatment" post="of patients with COVID-19 (32). A recent study showed"/>
  <result pre="Inhibits TMPRSS2 protease Inhibition of cell entry Prevents SARS-CoV-2 coronavirus" exact="infection" post="An in vitro study in a mouse model demonstrated"/>
  <result pre="camostat in protecting mice from death from a lethal SARS-CoV" exact="infection" post="with a 60% survival rate (34). It is considered"/>
  <result pre="clinical trials are needed (35). Mesylate camostat, approved in the" exact="treatment" post="of inflammation of the pancreas in Japan. Remdesivir Antiviral"/>
  <result pre="FDA (US) has authorized the use of remdesivir in severe" exact="infection" post="with the new coronavirus SARS-CoV-2, through the Special Emergency"/>
  <result pre="HIV Lopinavir is a protease inhibitor used to treat HIV" exact="infection" post="in combination with ritonavir to increase its availability. Lopinavir"/>
  <result pre="negative pregnancy test and always associated with contraceptive medication during" exact="treatment" post="and at least 7 days after stopping treatment; Doses:"/>
  <result pre="fatal consequences (42). Chloroquine [(N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine)], a conventional drug for the" exact="treatment" post="of malaria, has been applied in several studies against"/>
  <result pre="by abrogating the infection, resulting in the inhibition of SARS-CoV-2" exact="infection" post="and spread (44). Emergence of the HCoV strains such"/>
  <result pre="it may be tested as a future drug against viral" exact="infection" post="and spread. The molecular mechanism of the action of"/>
  <result pre="an anticoagulant and anti-pancreatitis agent and is approved for the" exact="treatment" post="of cystic fibrosis. Nafamostat has mucolytic action and can"/>
  <result pre="Remdesivir According to the WHO, the most promising candidate for" exact="treatment" post="of SARS-COV-2 is remdesivir (50, 51). Remdesivir is a"/>
  <result pre="patients with a suspected or confirmed severe form of the" exact="infection" post="(those who have blood oxygen saturation SpO2 â‰¤ 94%,"/>
  <result pre="without a control group in which patients received a remdesivir" exact="treatment" post="for 5 or 10 days. Results showed that clinical"/>
  <result pre="combination of lopinavir/ritonavir protease inhibitors (marketed as Kaletra for the" exact="treatment" post="of HIV infection), with or without IFNÎ², is another"/>
  <result pre="a team of experts from Wuhan (the city where the" exact="infection" post="began) developed a best practice guide, following the management"/>
  <result pre="Inhibitors Oseltamivir, peramivir, or zanamivir are not justified for the" exact="treatment" post="of COVID-19, because this virus has no neuraminidase; the"/>
  <result pre="medication is recommended for patients with COVID-19 until an exclusion" exact="diagnosis" post="of influenza by gene amplification test is carried out"/>
  <result pre="is carried out or for as long as necessary for" exact="treatment" post="of a concomitant infection with an influenza virus (60)."/>
  <result pre="for as long as necessary for treatment of a concomitant" exact="infection" post="with an influenza virus (60). Tocilizumab Tocilizumab is a"/>
  <result pre="stated that it can be prescribed for patients with coronavirus" exact="infection" post="who have severe lung damage and high levels of"/>
  <result pre="the only antibody available for immediate use in the potential" exact="treatment" post="of COVID-19 is found in plasma taken from cured"/>
  <result pre="from recovered patients, it can be used to perform a" exact="treatment" post="consisting of polyclonal hyperimmune immunoglobulin. Ongoing Clinical Studies Related"/>
  <result pre="lopinavir/ritonavir protease inhibitors (marketed under the name Kaletra for the" exact="treatment" post="of HIV infection), with or without IFNÎ², is a"/>
  <result pre="A team of experts from Wuhan (the city where the" exact="infection" post="occurred) developed a good practice guide, following the management"/>
  <result pre="first data analysis will be performed after 15 days of" exact="treatment" post="(70). COVACTA is a new study that aims to"/>
  <result pre="is a new study that aims to identify a potential" exact="treatment" post="against SARS-COV-2. The drug that will be investigated is"/>
  <result pre="use is based on the approval of tocilizumab as a" exact="treatment" post="in cytokine release syndrome (CRS), an inflammatory manifestation throughout"/>
  <result pre="are statistically significantly correlated with the severe evolution of the" exact="infection" post="(71). To test the impact of camostat mesilate on"/>
  <result pre="to test the hypothesis that nafamostat is useful in the" exact="treatment" post="of COVID-19 lung damage. This hypothesis is justified by"/>
  <result pre="(77). Recently, hydroxychloroquine was found to efficiently inhibit the SARS-CoV-2" exact="infection" post="in vitro through an anti-inflammatory mechanism (48). In a"/>
  <result pre="a single therapy (79). This clinical survey demonstrated that hydroxychloroquine" exact="treatment" post="is significantly associated with viral load reduction in SARS-CoV-2"/>
  <result pre="This might be a milestone preventive option in limiting the" exact="infection" post="and spread of SARS-CoV-2. In the case of umifenovir"/>
  <result pre="resulted in a higher cure rate after 7 days of" exact="treatment" post="in moderate cases of COVID-19 (71.4% in the favipiravir"/>
  <result pre="serum collected from patients with SARS-COV-2, which contains antibodies against" exact="infection" post="(25). However, a study involving plasma harvested from patients"/>
  <result pre="long and rigorous research process, followed by many years of" exact="testing" post="to meet stringent regulatory requirements. Thus, clinical trials for"/>
  <result pre="the concomitant administration with other vaccines and treatments. After the" exact="testing" post="phase, the vaccines must be approved by the regulatory"/>
  <result pre="developing a possible vaccine for COVID-19, currently in the pre-clinical" exact="testing" post="phase (98). The developing vaccine uses a BAT technology"/>
  <result pre="harvested, the antigen was purified and is currently undergoing pre-clinical" exact="testing" post="(99). The pharmaceutical industry and health authorities argue that"/>
  <result pre="(102). These could serve as a cure and could prevent" exact="infection" post="and viral replication. Some TCM and other herbal preparations"/>
  <result pre="&amp;amp; Koidz.), may enhance immunity and be beneficial for CoV" exact="infection" post="treatment (106). However, further evidence is needed. Several traditional"/>
  <result pre="Koidz.), may enhance immunity and be beneficial for CoV infection" exact="treatment" post="(106). However, further evidence is needed. Several traditional herbal"/>
  <result pre="as a potential conflict of interest. 1Coronavirus disease 2019 (COVID-19)" exact="treatment" post="guideline. References References 1.BogochIiWattsAThomas-BachliAHuberCKraemerMUGKhanK. Pneumonia of unknown aetiology in"/>
  <result pre="al.. Clinical characteristics and intrauterine vertical transmission potential of COVID-19" exact="infection" post="in nine pregnant women: a retrospective review of medical"/>
  <result pre="Lancet. (2020) 395:809â€&quot;15. 10.1016/S0140-6736(20)30360-332151335 23.HanWQuanBGuoYZhangJLuYFengGet al.. The course of clinical" exact="diagnosis" post="and treatment of a case infected with coronavirus disease"/>
  <result pre="395:809â€&quot;15. 10.1016/S0140-6736(20)30360-332151335 23.HanWQuanBGuoYZhangJLuYFengGet al.. The course of clinical diagnosis and" exact="treatment" post="of a case infected with coronavirus disease 2019. J"/>
  <result pre="12:322â€&quot;5. 10.1093/jmcb/mjaa01432236562 33.ChenJLiuDLiuLLiuPXuQXiaLet al.. [A pilot study of hydroxychloroquine in" exact="treatment" post="of patients with moderate COVID-19]. Zhejiang Da Xue Xue"/>
  <result pre="disease 2019 in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 pneumonia monitored by quantitative RT-PCR. J Korean"/>
  <result pre="in treating COVID-19. J Infect. (2020) 81:e21â€&quot;e23. 10.1016/j.jinf.2020.03.06032283143 39.LianNXieHLinSHuangJZhaoJLinQ. Umifenovir" exact="treatment" post="is not associated with improved outcomes in patients with"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin"/>
  <result pre="44.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.. Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol J. (2005) 2:69. 10.1186/1743-422X-2-6916115318 45.GordonCJTchesnokovEPFengJYPorterDPGotteM. The"/>
  <result pre="RanstMet al.. Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn mice. Antimicrob Agents Chemother. (2009) 53:3416â€&quot;21. 10.1128/AAC.01509-0819506054"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 49.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJIet al.."/>
  <result pre="April 20, 2020). 54.ChuCMChengVCHungIFWongMMChanKHChanKSet al.. Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findings. Thorax. (2004)"/>
  <result pre="SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19" exact="treatment" post="option. J Med Virol. (2020). 10.1002/jmv.2572932104907 56.BlaisingJPolyakSJPecheurEI. Arbidol as"/>
  <result pre="in Wuhan, China. JAMA. (2020) 323:1061â€&quot;9. 10.1001/jama.2020.158532031570 61.XuXHanMLiTSunWWangDFuBet al.. Effective" exact="treatment" post="of severe COVID-19 patients with tocilizumab. Proc Natl Acad"/>
  <result pre="64.BlochEMShohamSCasadevallASachaisBSShazBWintersJLet al.. Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19. J Clin Investig. (2020) 130:2757â€&quot;65. 10.1172/JCI13874532254064 65.ArturoCLiise-AnneP."/>
  <result pre="Treatment of Novel Coronavirus[Expert consensus on chloroquine phosphate for the" exact="treatment" post="of novel coronavirus pneumonia]. Zhonghua Jie He He Hu"/>
  <result pre="Zhi. (2020) 43:185â€&quot;8. 10.3760/cma.j.issn.1001-0939.2020.03.00932164085 75.MohammadiSJafariBAsgharianPMartorellMSharifi-RadJ. Medicinal plants used in the" exact="treatment" post="of Malaria: a key emphasis to Artemisia, Cinchona, Cryptolepis,"/>
  <result pre="(1983) 75:11â€&quot;8. 10.1016/0002-9343(83)91265-26408923 78.GautretPLagierJ-CParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="Dis. (2020) 11:462â€&quot;4. 10.14336/AD.2020.030132257554 85.YangYIslamMSWangJLiYChenX. Traditional Chinese medicine in the" exact="treatment" post="of patients infected with 2019-new coronavirus (SARS-CoV-2): a review"/>
  <result pre="and McF7 cell lines. Farmacia J. (2016) 64:82â€&quot;7. 105.GiteaDVicasSGiteaMANemethSTitDMPascaBet al.HPLC" exact="screening" post="of bioactives compounds and antioxidant capacity of different hypericum"/>
  <result pre="2011:731308. 10.1093/ecam/neq03221799689 122.JinYHCaiLChengZSChengHDengTFanYPet al.. A rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia"/>
  <result pre="122.JinYHCaiLChengZSChengHDengTFanYPet al.. A rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)."/>
 </snippets>
</snippetsTree>
